Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 307 results found since Jan 2013.
Study Raises Questions About Transfusions In PCI Patients
A very large observational study raises important questions about the role of transfusions in PCI patients in the US. In a study published in JAMA, researchers from Duke and Yale analyzed data from more than 2.25 million percutaneous coronary intervention (PCI) procedures at more than 1,400 hospitals. The data came from the CathPCI Registry, a large ongoing study that includes a significant proportion of all cardiac catheterization procedures in the US. The overall transfusion rate was 2.14% but there was a very wide variation in transfusion practice patterns, ranging from 0 to 13%…. …. Click here to read the More…
Source: CardioBrief - February 25, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics anemia PCI transfusions Source Type: blogs
FDA Approves New Catheter For Treatment Of Atrial Fibrillation
The FDA has granted marketing approval for the Thermocool Smarttouch ablation catheter for use in patients with drug-resistant paroxysmal atrial fibrillation (AF), sustained monomorphic ischemic ventricular tachycardia and Type I atrial flutter. The device is manufactured by Biosense Webster, a Johnson & Johnson company. … Click here to read the full post on Forbes.
Source: CardioBrief - February 25, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery Source Type: blogs
Victor Dzau Leaving Duke To Head The Institute Of Medicine
Cardiologist Victor Dzau will leave his positions as the chancellor for health affairs at Duke University and the CEO of the Duke University Health System to become the next president of the Institute of Medicine. He will replace Harvey Fineberg, who has been the IOM president for the last 12 years. “I am humbled and honored to be selected to lead the IOM at a time of unprecedented opportunities and challenges in health, health care, and biomedical sciences,” said Dzau in a statement from the IOM. “Harvey Fineberg has been an exceptional leader of the More…
Source: CardioBrief - February 19, 2014 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Duke Institute of Medicine Source Type: blogs
FDA Advisory Panel Recommends Against Approval Of Cangrelor
The FDA’s Cardiovascular and Renal Drugs Advisory Committee today recommended against the approval of cangrelor, the investigational new antiplatelet drug from the Medicines Company. In a 7-2 vote the panel first rejected an indication for the reduction of thrombotic cardiovascular events including stent thrombosis in patients undergoing PCI. The panel also voted unanimously to reject a second indication… … Click here to read the full post on Forbes.
Source: CardioBrief - February 12, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics antiplatelet Cangrelor clopidogrel FDA PCI Source Type: blogs
FDA Reviewers Deliver Split Opinion On The Medicines Company’s Cangrelor
FDA reviewers presented two dramatically different views of The Medicines Company’s investigational new drug cangrelor. One reviewer says the drug should not be approved without a new trial and even states that the CHAMPION trials “were conducted unethically” and should not be approved “on that fact alone.” But two other reviewers recommend approval. … Click here to read the full post on Forbes.
Source: CardioBrief - February 10, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics antiplatelet therapy Cangrelor FDA advisory panel PCI Source Type: blogs
Leading European Cardiologist Accused Of Plagiarism
Thomas Lüscher, the editor of the European Heart Journal and one of the most prominent cardiologists in Europe, has been accused of plagiarism. An irony in the case is that Lüscher has taken a strong public position against scientific misconduct of all sorts, including plagiarism. … Click here to read the full post on Forbes.
Source: CardioBrief - February 10, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes European Heart Journal Lüscher plagiaism scientific misconduct Source Type: blogs
Eric Topol To Be AT&T’s Chief Medical Advisor
AT&T announced today that it had appointed cardiologist Eric Topol as its Chief Medical Advisor. The company said he will “impact the design, development and delivery of AT&T’s healthcare IT solutions, connecting the healthcare ecosystem to enhance health outcomes and care delivery processes for patients and their caregivers.” … Click here to read the full post on Forbes.
Source: CardioBrief - February 5, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events big data Eric Topol mobile Source Type: blogs
More Guideline Controversy: Blood Pressure Expert Decries ‘Political Correctness’
Now add “political correctness” to the long list of criticisms directed against the recent publication of new and updated cardiovascular guidelines. One leading hypertension expert writes that the authors of the recent AHA/ACC/CDC Science Advisory on blood pressure control were chosen not for their expertise but for political expediency. … Click here to read the full post on Forbes. Confusion (Photo credit: quinn.anya)
Source: CardioBrief - February 3, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes American College of Cardiology american heart association blood pressure Guideline hypertension Source Type: blogs
American College of Cardiology Announces Late-Breaking Clinical Trials
The American College of Cardiology announced the lineup of late-breaking clinical trials for its upcoming annual meeting in Washington, DC. The opening session will include the most eagerly anticipated trials– the main results of Symplicity HTN-3 and the comparison of Corevalve and surgery in high risk patients. Subsequent sessions will include several phase 3 trials of PCSK9 inhibitors. Here is the complete list of trials: … Click here to read the full post on Forbes.
Source: CardioBrief - January 31, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events ACC late-breakers Scientific Sessions Source Type: blogs
Problems Persist Despite Gains In Oral Anticoagulant Use
Although significant progress has been made in recent years, a new survey from the European Society of Cardiology finds that there are still too many atrial fibrillation patients who are not taking the best medications to reduce their elevated risk of stroke. Many elderly patients are not receiving oral anticoagulants and overall too many patients are still taking aspirin, despite the fact that it is not recommended for this group of patients. In a paper published in the American Journal of Medicine, Gregory YH Lip and colleagues analyzed data from more than 3,100 patients surveyed in the Euro More…
Source: CardioBrief - January 28, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Policy & Ethics Prevention, Epidemiology & Outcomes AF anticoagulants atrial fibrillation oral anticoagulants stroke Source Type: blogs
Stent Remains Available Despite Trial Showing Dangers
A leading critic says that the FDA has been remiss for not removing a stent from the market although strong evidence exists that its use leads to more deaths and strokes. … Now, in a paper published in BMJ, a group of physicians led by Rita Redberg say that by not removing Wingspan from the market the FDA is shirking its “responsibility to protect the public’s health.” … Click here to read the full post on Forbes.
Source: CardioBrief - January 23, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics FDA intracranial stent Stryker Wingspan Source Type: blogs
Dangerous Rapid Calcification Observed In Pediatric Patients After Aortic Valve Replacement
Pediatric cardiac surgeons at Boston Children’s Hospital are warning the medical community about a potentially fatal problem in children and young adults who received a bioprosthetic valve manufactured by Sorin. The surgeons initially became concerned when a young asymptomatic patient died suddenly after her valve underwent rapid calcification, only 7 months after a routine followup echocardiogram found no signs of blockage. … Click here to read the entire post on Forbes.
Source: CardioBrief - January 21, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics aortic valve replacement congenital aortic valve disease Mitroflow pediatrics Sorin Source Type: blogs
FDA Grants Earlier Than Expected Approval For Medtronic’s CoreValve
The FDA today approved Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery. The approval came several months ahead of expectations and without an FDA advisory panel meeting. … Click here to read the full post on Forbes.
Source: CardioBrief - January 17, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events aortic valve replacement CoreValve Sapien TAVI TAVR Source Type: blogs
Pivotal Medtronic Trial For ‘Breakthrough’ Blood Pressure Device Goes Down The Tubes
The hypertension community woke up this morning to a large dose of reality with an announcement by Medtronic that the novel SYMPLICITY HTN-3 trial of its much-anticipated renal denervation device had failed to meet its primary efficacy endpoint. Renal denervation has been widely touted as a breakthrough product that could dramatically lower blood pressure by as much as 30 mm Hg, allowing physicians to cure the most severe form of high blood pressure, resistant hypertension. “SYMPLICITY HTN-3 met its primary safety endpoint related to the incidence of major adverse events one month following randomization and r...
Source: CardioBrief - January 9, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes blood pressure hypertension Medtronic renal denervation Source Type: blogs
Hospital Quality Helps Explain Some Of The Racial Disparities In Outcomes After CABG
It has long been known that racial disparities exist in health care. A large body of research has found that nonwhite patients have worse outcomes than whites. But it has been difficult to understand the underlying reasons for these disparities. Now a new study offers evidence that, at least in the case of bypass surgery, a significant but by no means complete portion of this disparity is due to decreased access among nonwhites to high quality hospitals. In a paper published in JAMA Surgery, Govind Rangrass and colleagues analyzed Medicare data from 173,925 CABG patients. 8.6% of the More…
Source: CardioBrief - January 8, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes bypass surgery CABG Medicare racial disparities Source Type: blogs
